AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31429418 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM)
Number of subjects: 122
Study 31429418 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 122
Study 27492865 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GL diet
Number of subjects: 22
Study 27492865 — intervention group
Group type: COMPARATOR
Intervention: Low Fat diet
Number of subjects: 22
Study 26854207 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation survey reviewed by clinician
Number of subjects: 304
Study 26854207 — intervention group
Group type: COMPARATOR
Intervention: Expectation survey not reviewed (Control group)
Number of subjects: 304
Study 26854207 — intervention group
Group type: COMPARATOR
Intervention: No expectation survey (Baseline group)
Number of subjects: 304
Study 24952697 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 5011
Study 24952697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5011
Study 22420645 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) with intrathecal bupivacaine 2.5 mg and fentanyl 5 μg
Number of subjects: 115
Study 22420645 — intervention group
Group type: COMPARATOR
Intervention: Epidural with bupivacaine 20 mg and fentanyl 40 μg
Number of subjects: 115
Study 22420645 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE)
Number of subjects: 115
Study 20637249 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate plus risperidone
Number of subjects: 40
Study 20637249 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus risperidone
Number of subjects: 40
Study 17895472 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sorafenib
Number of subjects: 150
Study 17895472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 15863745 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff training programme
Number of subjects: 10
Study 15863745 — intervention group
Group type: COMPARATOR
Intervention: Control homes
Number of subjects: 10
Study 12036673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (100 mg)
Number of subjects: 15
Study 12036673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9880383 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomethiazole (75 mg/kg)
Number of subjects: 1360
Study 9880383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1360
Study 9880383 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomethiazole
Number of subjects: 1360
Study 9880383 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomethiazole (in TACS subgroup)
Number of subjects: 1360
Study 9880383 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in TACS subgroup)
Number of subjects: 1360
Study 7485006 — intervention group
Group type: EXPERIMENTAL
Intervention: Through-the-scope manometry
Number of subjects: 12
Study 7485006 — intervention group
Group type: COMPARATOR
Intervention: Laboratory testing
Number of subjects: 12
Study 2023212 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 148
Study 2023212 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 148
Study 2023212 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 148
Study 7130643 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuations of repetitions (AAAAA)
Number of subjects: 20
Study 7130643 — intervention group
Group type: COMPARATOR
Intervention: Discontinuations of alternations (BBBBA)
Number of subjects: 20
Study 7130643 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 latencies for elderly women
Number of subjects: 20
Study 7130643 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean reaction time
Number of subjects: 20
Study 31627723 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM)
Number of subjects: 40
Study 31627723 — intervention group
Group type: COMPARATOR
Intervention: Sham MWM
Number of subjects: 40
Study 28870107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine 3.5 mg/kg
Number of subjects: 806
Study 28870107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 806
Study 26590130 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise (60-min sessions, 3 times per week for 3 months)
Number of subjects: 145
Study 26590130 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 145
Study 25157992 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and surgery (case group)
Number of subjects: 22
Study 25157992 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 22
Study 22067237 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational music
Number of subjects: 20
Study 22067237 — intervention group
Group type: COMPARATOR
Intervention: No music (control)
Number of subjects: 20
Study 19349341 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy
Number of subjects: 14
Study 17487652 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg 17beta‐estradiol (E2) + 0.25 mg norethisterone acetate (NETA)
Number of subjects: 154
Study 17487652 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg E2 + 0.1 mg NETA
Number of subjects: 154
Study 17487652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 15519264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 13
Study 15519264 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 13
Study 15519264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 12901541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg)
Number of subjects: 111
Study 12901541 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (3 mg)
Number of subjects: 111
Study 11578015 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (200 microg/d)
Number of subjects: 55
Study 11578015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 9635933 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg twice daily for 3 weeks)
Number of subjects: 22
Study 9635933 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 microg twice daily for 3 weeks)
Number of subjects: 22
Study 9635933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9635933 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 22
Study 9635933 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 22
Study 7880946 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-session biofeedback training with visual and auditory feedback
Number of subjects: 40
Study 7880946 — intervention group
Group type: EXPERIMENTAL
Intervention: Labile group (23 subjects)
Number of subjects: 40
Study 7880946 — intervention group
Group type: COMPARATOR
Intervention: Stabile group (17 subjects)
Number of subjects: 40
Study 3275894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg every six hours)
Number of subjects: 186
Study 3275894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 8235685 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive, non-elastic tape
Number of subjects: 112
Study 8235685 — intervention group
Group type: COMPARATOR
Intervention: Confection brace
Number of subjects: 112
Study 8235685 — intervention group
Group type: EXPERIMENTAL
Intervention: Total population
Number of subjects: 112
Study 849673 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (high dose)
Number of subjects: 6
Study 849673 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (low dose)
Number of subjects: 6
Study 849673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 849673 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (high and low doses)
Number of subjects: 6
Study 31107130 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-shooting sport practiced once a week for 6 months
Number of subjects: 128
Study 31107130 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 128
Study 31107130 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-shooting sport
Number of subjects: 128
Study 29578594 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-intervention group (PCPs received CME and patients received mailers with educational materials and FOBT kits)
Number of subjects: 3120
Study 29578594 — intervention group
Group type: COMPARATOR
Intervention: Delayed-intervention group (PCPs received no CME and patients received mailers in year 2)
Number of subjects: 3120
Study 29578594 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect of the mailer intervention (with or without CME)
Number of subjects: 3120
Study 29578594 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact on rates of colonoscopy or sigmoidoscopy
Number of subjects: 3120
Study 26421384 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast Consumption (BC)
Number of subjects: 8
Study 26421384 — intervention group
Group type: COMPARATOR
Intervention: Breakfast Omission (BO)
Number of subjects: 8
Study 24669314 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous aerobic exercise training (CONT)
Number of subjects: 38
Study 24669314 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Number of subjects: 38
Study 24669314 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 38
Study 22208805 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 40 mg with 240 mL of ethanol 20%
Number of subjects: 0
Study 22208805 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone CRF 40 mg with 240 mL of ethanol 20%
Number of subjects: 0
Study 22208805 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 40 mg with 240 mL of ethanol 40%
Number of subjects: 0
Study 22208805 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone CRF 40 mg with 240 mL of ethanol 40%
Number of subjects: 0
Study 22208805 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER and CRF with ethanol (0 to 40%)
Number of subjects: 0
Study 19843057 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib
Number of subjects: 0
Study 17620445 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes personal trainer intervention (six self‐monitoring, goal‐setting, and problem‐solving sessions with trained nonprofessionals)
Number of subjects: 81
Study 17620445 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 81
Study 15848604 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (C0 monitoring)
Number of subjects: 700
Study 15848604 — intervention group
Group type: COMPARATOR
Intervention: Neoral (cyclosporine microemulsion, C2 monitoring)
Number of subjects: 700
Study 11872346 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (T)
Number of subjects: 283
Study 11872346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential methotrexate and 5-fluorouracil (MF)
Number of subjects: 283
Study 10640879 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (group A)
Number of subjects: 67
Study 10640879 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% (group B)
Number of subjects: 67
Study 10640879 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.0625% (group C)
Number of subjects: 67
Study 10640879 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 67
Study 8523236 — intervention group
Group type: EXPERIMENTAL
Intervention: D-[U-13C]glucose (100 mg/kg)
Number of subjects: 10
Study 8523236 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 10% dextrose (D10W)
Number of subjects: 10
Study 2311588 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (L-C)
Number of subjects: 7
Study 2311588 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 7
Study 7454128 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 2 (linoleic acid rich): carbohydrates 45 cal%, fats 40 cal% (one third linoleic acid), proteins 15 cal%.
Number of subjects: 102
Study 7454128 — intervention group
Group type: COMPARATOR
Intervention: Diet 1 (linoleic acid poor): carbohydrates 50 cal%, saturated fats 35 cal%, proteins 15 cal%.
Number of subjects: 102
Study 7454128 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 2 (linoleic acid rich).
Number of subjects: 102
Study 7454128 — intervention group
Group type: COMPARATOR
Intervention: Diet 1 (linoleic acid poor).
Number of subjects: 102
Study 7454128 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 2 (linoleic acid rich) for females.
Number of subjects: 102
Study 7454128 — intervention group
Group type: COMPARATOR
Intervention: Diet 1 (linoleic acid poor) for females.
Number of subjects: 102
Study 7454128 — intervention group
Group type: COMPARATOR
Intervention: Diet 1 (linoleic acid poor) for males.
Number of subjects: 102
Study 31678837 — intervention group
Group type: EXPERIMENTAL
Intervention: Full branding
Number of subjects: 9987
Study 31678837 — intervention group
Group type: COMPARATOR
Intervention: Plain packaging or brand logo
Number of subjects: 9987
Study 31678837 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warnings present
Number of subjects: 9987
Study 31678837 — intervention group
Group type: EXPERIMENTAL
Intervention: Edible gummies
Number of subjects: 9987
Study 31678837 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-18 and 19-35 year-olds rating of edible gummies
Number of subjects: 9987
Study 29071983 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 41
Study 29071983 — intervention group
Group type: COMPARATOR
Intervention: Control (rehabilitation training only)
Number of subjects: 41
Study 26415058 — intervention group
Group type: COMPARATOR
Intervention: 2‐session adolescent only (BI‐A)
Number of subjects: 259
Study 26415058 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐session adolescent and additional parent session (BI‐AP)
Number of subjects: 259
Study 23659182 — intervention group
Group type: EXPERIMENTAL
Intervention: KiVa Antibullying Program
Number of subjects: 9912
Study 23659182 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 9912
Study 21795439 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-course lunch consumed in 0.5 hours
Number of subjects: 38
Study 21795439 — intervention group
Group type: COMPARATOR
Intervention: 4-course lunch consumed in 2 hours
Number of subjects: 38
Study 21795439 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in ghrelin concentrations
Number of subjects: 38
Study 19577020 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Traumatic Brain Injury (MTBI)
Number of subjects: 4144
Study 19577020 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic Stress Disorder (PTSD)
Number of subjects: 4144
Study 19577020 — intervention group
Group type: COMPARATOR
Intervention: Healthy Control
Number of subjects: 4144
Study 19577020 — intervention group
Group type: COMPARATOR
Intervention: MVC Injury Control
Number of subjects: 4144
Study 17261652 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg clopidogrel daily maintenance dose
Number of subjects: 40
Study 17261652 — intervention group
Group type: COMPARATOR
Intervention: 75 mg clopidogrel daily maintenance dose
Number of subjects: 40
Study 15121342 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproate (VPA)
Number of subjects: 0
Study 15121342 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (mood stabilizers plus anti-psychotic agents)
Number of subjects: 0
Study 12081337 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence at induction
Number of subjects: 118
Study 12081337 — intervention group
Group type: COMPARATOR
Intervention: Parental absence at induction
Number of subjects: 118
Study 9449494 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-cromolyn sodium
Number of subjects: 325
Study 9449494 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC-cromolyn sodium
Number of subjects: 325
Study 9449494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 7874944 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited pulmonary rehabilitation program focused on coping strategies for shortness of breath (6-week treatment)
Number of subjects: 89
Study 7874944 — intervention group
Group type: COMPARATOR
Intervention: General health education control group
Number of subjects: 89
Study 2571815 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (weekly supportive group therapy with self-hypnosis for pain)
Number of subjects: 86
Study 2571815 — intervention group
Group type: COMPARATOR
Intervention: Routine oncological care (Control group)
Number of subjects: 86
Study 930916 — intervention group
Group type: EXPERIMENTAL
Intervention: Total duration of oral contraceptive use
Number of subjects: 17942
Study 30458499 — intervention group
Group type: EXPERIMENTAL
Intervention: High-deductible insurance plan
Number of subjects: 328899
Study 30458499 — intervention group
Group type: COMPARATOR
Intervention: Low-deductible insurance plan
Number of subjects: 328899
Study 26169870 — intervention group
Group type: COMPARATOR
Intervention: Salmon twice weekly (IG-F)
Number of subjects: 158
Study 26169870 — intervention group
Group type: COMPARATOR
Intervention: ALA-rich rapeseed oil (IG-R)
Number of subjects: 158
Study 25041550 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical mechanical periodontal treatment (test group, n = 32)
Number of subjects: 64
Study 25041550 — intervention group
Group type: COMPARATOR
Intervention: Delayed periodontal treatment (control group, n = 32)
Number of subjects: 64
Study 22741027 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based psychodynamic guided self-help treatment consisting of nine treatment modules with online therapist contact for 10 weeks.
Number of subjects: 92
Study 22741027 — intervention group
Group type: COMPARATOR
Intervention: Active control condition consisting of a structured support intervention with psychoeducation and scheduled weekly contacts online for 10 weeks.
Number of subjects: 92
Study 20180933 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed tablets with concomitant meal
Number of subjects: 899
Study 20180933 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible tablets with concomitant meal
Number of subjects: 899
Study 20180933 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed tablets with milk
Number of subjects: 899
Study 20180933 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible tablets with milk
Number of subjects: 899
Study 20180933 — intervention group
Group type: COMPARATOR
Intervention: Evaluable population (not food-related)
Number of subjects: 899
Study 18288237 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus crispatus CTV‐05 vaginal suppository
Number of subjects: 30
Study 18288237 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal suppository
Number of subjects: 30
Study 15754230 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative knee aspiration
Number of subjects: 86
Study 15754230 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative arthroscopic biopsy
Number of subjects: 86
Study 15754230 — intervention group
Group type: COMPARATOR
Intervention: Preoperative arthroscopic biopsy and aspiration
Number of subjects: 86
Study 15754230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 86
Study 12419098 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemirolast potassium 0.1% ophthalmic solution
Number of subjects: 274
Study 12419098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 9860152 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg alone
Number of subjects: 11
Study 9860152 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine 10 mg after 2 weeks of carbamazepine 200 mg BID
Number of subjects: 11
Study 7630145 — intervention group
Group type: COMPARATOR
Intervention: Almokalant (12.8 mumol)
Number of subjects: 0
Study 7630145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2774884 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzocaine spray
Number of subjects: 8
Study 2774884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air spray)
Number of subjects: 8
Study 897864 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C therapy
Number of subjects: 0
Study 897864 — intervention group
Group type: EXPERIMENTAL
Intervention: L-leucine therapy
Number of subjects: 0
Study 897864 — intervention group
Group type: EXPERIMENTAL
Intervention: Single loading dose of L-tryptophan
Number of subjects: 0
Study 897864 — intervention group
Group type: EXPERIMENTAL
Intervention: Single loading doses of L-kynurenine
Number of subjects: 0
Study 31079282 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs) - Exemestane and Letrozole
Number of subjects: 100
Study 27472858 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot-pack + laser therapy 1 (850 nm Ga-Al-As laser)
Number of subjects: 49
Study 27472858 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot-pack + laser therapy 2 (650 nm He-Ne, 785 ve 980 nm Ga-Al-As combined plaque laser)
Number of subjects: 49
Study 26141942 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (3 sets of 3‐min cycling with a 2‐min active rest between sets, 180 kcal)
Number of subjects: 26
Study 26141942 — intervention group
Group type: COMPARATOR
Intervention: MICT (45 min, 360 kcal)
Number of subjects: 26
Study 26141942 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HIIT and MICT followed by a 4‐week LCDi
Number of subjects: 26
Study 26141942 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 26
Study 24011850 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness management and recovery
Number of subjects: 118
Study 24011850 — intervention group
Group type: COMPARATOR
Intervention: Problem solving control
Number of subjects: 118
Study 21357809 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearlong home-based exercise program (Exercise Plus Program)
Number of subjects: 180
Study 21357809 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 180